Characterization of ARC-111 as a Novel Topoisomerase I-Targeting Anticancer Drug

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8400-8407

  Li, Tsai Kun ^c,d   Houghton, Peter J ^b   Desai, Shyamal D ^a   Daroui, Parima ^a   Liu, Angela A ^a   Hars, Eszter S ^a   Ruchelman, Alexander L ^c   LaVoie, Edmond J ^c   Liu, Leroy F ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

8,9 DIMETHOXY 5 (2 N,N DIMETHYLAMINOETHYL) 2,3 METHYLENEDIOXY 5H DIBENZO[CH][1,6]NAPHTHYRIDIN 6 ONE; ANTINEOPLASTIC AGENT; ARC 111; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; DNA TOPOISOMERASE; IRINOTECAN; SERUM ALBUMIN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMET ASSAY; DNA TOPOISOMERASES, TYPE I; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, SCID; NAPHTHYRIDINES; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROTEIN BINDING; SERUM ALBUMIN; WILMS TUMOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0346365368     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wall, M. E., and Wani, M. C. Camptothecin. Discovery to clinic. Ann. N. Y. Acad. Sci., 803: 1-12, 1996.
2. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Wash. DC), 246: 1046-1048, 1989.
3. Gottlieb, J. A., and Luce, J. K. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 56: 103-105, 1972.
4. Chang, A. Y. The potential role of topotecan in the treatment of advanced breast cancer. Semin. Oncol., 24: S20, 1997.
5. Rosen, L. S. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Huntingt), 12: 103-109, 1998.
6. Hsiang, Y. H., and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
7. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
8. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
9. Nitiss, J. L., and Wang, J. C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol., 50: 1095-1102, 1996.
10. Porter, S. E., and Champoux, J. J. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res., 17: 8521-8532, 1989.
11. D'Arpa, P., Beardmore, C., and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
12. Hsiang, Y. H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077-5082, 1989.
13. Tsao, Y. P., D'Arpa, P., and Liu, L. F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res., 52: 1823-1829, 1992.
14. Li, T-K., and Liu, L. F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol., 41: 53-77, 2001.
15. Coleman, L. W., Rohr, L. R., Bronstein, I. B., and Holden, J. A. Human DNA topoisomerase 1: An anticancer drug target present in human sarcomas. Hum. Pathol., 33: 599-607, 2002.
16. Lynch, B. J., Komaromy-Hiller, G., Bronstein, I. B., and Holden, J. A. Expression of DNA topoisomerase I, DNA topoisomerase II-α, and p53 in metastatic malignant melanoma. Hum. Pathol., 29: 1240-1245, 1998.
17. Desai, S. D., Zhang, H., Rodriguez-Bauman, A., Yang, J. M., Wu, X., Gounder, M. K., Rubin, E. H., and Liu, L. F. Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol. Cell. Biol., 23: 2341-2350, 2003.
18. Desai, S. D., Liu, L. F., Vazquez-Abad, D., and D'Arpa, P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem., 272: 24159-24164, 1997.
19. Beidler, D. R., and Cheng, Y. C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol., 47: 907-914, 1995.
20. Desai, S. D., Li. T. K., Rodriguez-Bauman, A., Rubin, E. H., and Liu, L. F. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res., 61: 5926-5932, 2001.
21. Mao, Y., Sun, M., Desai, S. D., and Liu, L. F. SUMO-1 conjugation to topoisomerase 1: A possible repair response to topoisomerase-mediated DNA damage. Proc. Natl. Acad. Sci. USA, 97: 4046-4051, 2000.
22. Adams, D. J., Dewhirst, M. W., Flowers, J. L., Gamcsik, M. P., Colvin, O. M., Manikumar, G., Wani, M. C., and Wall, M. E. Camptothecin analogues with enhanced antitumor activity at acidic pH. Cancer Chemother. Pharmacol., 46: 263-271, 2000.
23. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
24. Maliepaard, M., van Gastelen, M. A., Tohgo, A., Hausheer, F. H., van Waardenburg, R. C., de Jong, L. A., Pluim, D., Beijnen, J. H., and Schellens, J. H. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin. Cancer Res., 7: 935-941, 2001.
25. Yang, C. H., Schneider, E., Kuo, M. L., Volk, E. L., Rocchi, E., and Chen, Y. C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem. Pharmacol., 60: 831-837, 2000.
26. Burke, T. G., and Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem., 37: 40-46, 1994.
27. Mi, Z., and Burke, T. G. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry, 33: 12540-12545, 1994.
28. Mi, Z., Malak, H., and Burke, T. G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry, 34: 13722-13728, 1995.
29. Ruchelman, A. L., Singh, S. K., Wu, X. H., Ray, A., Yang, J-M., Li, T-K., Liu, A., Liu, L. F., and LaVoie, E. J. Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435. Bioorg. Med. Chem. Lett., 12: 3333-3336, 2002.
30. Ruchelman, A. L., Singh, S. K., Wu, X., Ray, A., Yang, J. M., Li, T-K., Liu, A., Liu, L. F., and LaVoie. E. J. 5H-Dibenzo[c. h]naphthyridin-6-ones: Novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg. Med. Chem., 11: 2061-2073, 2003.
31. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
32. Andoh, T., Ishii, K., Suzuki, Y., Ikegami, Y., Kusunoki, Y., Takemoto, Y., and Okada, K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. Natl. Acad. Sci. USA, 84: 5565-5569. 1987.
33. Woessner, R. D., Eng, W. K., Hofmann, G. A., Rieman, D. J., McCabe, F. L., Hertzberg, R. P., Mattern, M. R., Tan, K. B., and Johnson, R. K. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res., 4: 481-488, 1992.
34. Rubin, E., Pantazis, P., Bharti, A., Toppmeyer, D., Giovanella, B., and Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem., 269: 2433-2439, 1994.
35. Gervasoni, J. E., Jr., Fields, S. Z., Krishna, S., Baker, M. A., Rosado, M., Thuraisamy, K., Hindenburg. A. A., and Taub. R. N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res., 51: 4955-4963, 1991.
36. Fernandes, D. J., Danks, M. K., and Beck, W. T. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry, 29: 4235-4241, 1990.
37. Furman, W., Stewart, C. F., Poquette, C., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffman, P. C., Meyer, W. H., Pappo, A. S., Walter, A. W., and Houghton, P. J. The direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J. Clin. Oncol., 17: 1815-1824, 1999.
38. Godard, T., Deslandes, E., Sichel, F., Poul, J. M., and Gauduchon, P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat. Res., 520: 47-56, 2002.
39. Fu, Q., Kim, S. W., Chen, H. X., Grill, S., and Cheng, Y. C. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death. Mol. Pharmacol., 55: 677-683, 1999.
40. Roninson, I. B., Chin, J. E., Choi, K. G., Gros, P., Housman, D. E., Fojo, A., Shen, D. W., Gottesman. M. M., and Pastan, I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc. Natl. Acad. Sci. USA. 83: 4538-4542, 1986.
41. Liehr, J. G., Ahmed, A. E., and Giovanella. B. C. Pharmacokinetics of camptothecins administered orally. Ann. N. Y. Acad. Sci., 803: 157-163, 1996.